Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C Peral
Prm42 - Cost Model of Switching From Enbrel to Etanercept Biosimilars, for Non Medical Reasons, in Rheumatoid Arthritis Patients in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pms51 - Cost-Effectiveness of Tofacitinib-Containing Sequences for Rheumatoid Arthritis Patients in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Etanercept: Therapeutic Use in Patients With Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Anti-Atherosclerotic Effects of Etanercept in Rheumatoid Arthritis Patients
Japanese Journal of Clinical Immunology
Pharmacogenetics of Etanercept in Rheumatoid Arthritis
Pharmacogenomics
Molecular Medicine
Genetics
Pharmacology
Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Cost-Effectiveness of Early Treatment With Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients With Established Rheumatoid Arthritis
Advances in Therapy
Medicine
Pharmacology
Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Etanercept May Induce Neurosarcoidosis in a Patient Treated for Rheumatoid Arthritis
BMC Neurology
Medicine
Neurology
Anti-Drug Antibodies in Colombian Patients With Rheumatoid Arthritis Treated With Enbrel vs Etanar – Preliminary Report
Journal of Immunotoxicology
Toxicology
Immunology
